Error loading player: No playable sources found
ISPT02
Introducing GEMTESA® (vibegron) 75 mg tablets for the Treatment of Overactive Bladder (OAB) - Urovant
Date
March 4, 2021
Free
Standard Price
Introducing GEMTESA® (vibegron) 75 mg tablets for the Treatment of Overactive Bladder (OAB)
An Overview of OAB Implications and Challenges and a New Treatment Option for Long-Term Care
Supported by Urovant Sciences: This product theater will discuss the clinical profile and prescribing information for GEMTESA® (vibegron) 75mg tablets, for the treatment of Overactive Bladder. The presentation will also review challenges and implications associated with overactive bladder in long term care.
Speaker
Cathy Yaggy, MSN, GNP-BC
Director of Primary Care, Eventus WholeHealth
Related Products
Current Cardiac Medications
This session provides an overview of new medicines available for cardiac conditions. Focus includes pharmacological treatment in adult and geriatric populations with cardiac disease such as heart failure, atrial fibrillation, and coronary disease…
Monoclonal Antibodies for COVID-19 in Long-Term Care Facilities
This session discusses the use of monoclonal antibodies for COVID-19 in long-term care facilities…
CBD and THC Use and Indications in the Gerontological Population
This session discusses THC (tetrahydrocannabinol) and CBD (cannabidiol) products, summarizes the evidence surrounding THC and CBD uses in the gerontological population, and applies appropriate treatment plans incorporating THC and CBD products…
Acute Pain Management and Opioid Prescribing Regulations
This presentation is designed to educate gerontology nurse practitioners on safe and effective pain management using opioids. The presentation also explores risk and vulnerabilities of older adults…
